NOT KNOWN FACTUAL STATEMENTS ABOUT HEMGENIX

Quantity of eligible individuals: CDEC mentioned the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are categorised as owning moderate or reasonable condition might have a serious blee